ADC Therapeutics SA Q2 2025 Earnings Recap

ADC Therapeutics reported solid Q2 2025 performance, with net product revenues reaching $18.1 million, and promising clinical data for its ZYNLONTA treatments positioning the company for significant growth.

Key Takeaways

• Net product revenues increased slightly year-over-year to $18.1 million in Q2 and $35.5 million in the first half of 2025.
• ZYNLONTA plus glofitamab demonstrated a remarkable overall response rate of 93.3% in the LOTIS-7 trial, with plans to expand enrollment to 100 patients.
• The company is streamlining its operations by focusing solely on ZYNLONTA and a PSMA-targeting ADC, leading to a 30% workforce reduction.
• Continued development in late-stage trials is expected; LOTIS-5 is on track for key data by year-end 2025, potentially enhancing ZYNLONTA's market footprint.
• The completion of a $100 million private placement extends the company’s cash runway into 2028, supporting its strategic initiatives and growth plans.